The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis.
It is well established that some patients with diffuse large B-cell lymphoma (DLBCL) and the negative end of treatment PET-CT (EOT-PET-CT) will relapse, while a proportion with positive uptake can still obtain long-term EFS. We reviewed data of 200 consecutive, previously untreated patients with DLBCL recorded in Italy and Israel between 2007 and 2015. We found that patients with negative EOT-PET-CT with AMC > 630/mmc have a 3-years EFS of 72%, compared to those with AMC ≤ 630/mmc that have an EFS of 84%. Furthermore, considering patients with positive EOT-PET-CT, those with AMC > 630/mmc have a 3-years EFS of 8%, while those with AMC ≤ 630/mmc have an EFS of 38%. Thus, it appears that combining the gold standard for response evaluation EOT-PET-CT with a simple and inexpensive parameter like AMC at diagnosis, further improves prognostication in DLBCL. Applying this simple method can be useful for all doctors working in lymphoma clinical practice.
['Marcheselli|Raffaella|R|', 'Franceschetto|Antonella|A|', 'Sacchi|Stefano|S|', 'Bari|Alessia|A|', 'Levy|Ilana|I|', 'Pizzichini|Patrizia|P|', 'Prosperi|Daniela|D|', "D'Apollo|Rosaria|R|", 'Massi|Lucia|L|', 'Casolo|Alessandra|A|', 'Pozzi|Samantha|S|', 'Marcheselli|Luigi|L|', 'Tadmor|Tamar|T|', 'Prandini|Napoleone|N|', 'Cox|Maria Christina|MC|']
D000328:Adult D000368:Aged D000369:Aged, 80 and over D003131:Combined Modality Therapy D005260:Female D019788:Fluorodeoxyglucose F18 D006801:Humans D007958:Leukocyte Count D016403:Lymphoma, Large B-Cell, Diffuse D008297:Male D008875:Middle Aged D009000:Monocytes D000072078:Positron Emission Tomography Computed Tomography D011379:Prognosis D016016:Proportional Hazards Models D016896:Treatment Outcome D055815:Young Adult
DLBCL EOT-PET-CT AMC prognosis